Do Anti-Biofilm Antibiotics Have a Place in the Treatment of Diabetic Foot Osteomyelitis? - Université de Lille Accéder directement au contenu
Article Dans Une Revue Antibiotics Année : 2023

Do Anti-Biofilm Antibiotics Have a Place in the Treatment of Diabetic Foot Osteomyelitis?

Résumé

The choice of antibiotic regimens for use in patients presenting with diabetic foot osteomyelitis and their duration differs according to the situation. Antibiotics play a more important role in the medical option where no infected bone has been resected, while their role is reduced but not negligible in the case of surgical options. Some studies have reported the presence of biofilm structures in bone samples taken from patients with diabetic foot osteomyelitis, which raises the question of the place of anti-biofilm antibiotic regimens in this setting. During the last two decades, clinical studies have suggested a potential benefit for anti-biofilm antibiotics, mainly rifampicin against staphylococci and fluoroquinolones against gram-negative bacilli. However, no data from randomized controlled studies have been reported so far. The present work provides a summary of the available data on the question of the place of anti-biofilm antibiotics for the treatment of diabetic foot osteomyelitis, but also the potential limitations of such treatments. Keywords: diabetic foot osteomyelitis; biofilm; antimicrobial resistance; adverse effects; rifampicin; fluoroquinolones
Fichier principal
Vignette du fichier
antibiotics-12-00317.pdf (937.81 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04544068 , version 1 (12-04-2024)

Licence

Identifiants

Citer

Eric Senneville, Benoit Gachet, Nicolas Blondiaux, Olivier Robineau. Do Anti-Biofilm Antibiotics Have a Place in the Treatment of Diabetic Foot Osteomyelitis?. Antibiotics, 2023, Antibiotics, 12, ⟨10.3390/antibiotics12020317⟩. ⟨hal-04544068⟩

Collections

UNIV-LILLE
1 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More